The Korean pharmaceutical bio industry is making a bid into the electronic drug market for Alzheimer's disease. Recently, Remed unveiled the results of its transcranial magnetic stimulation (TMS) therapy that demonstrated an effect in treating Alzheimer's disease. AriBio, which is developing a new drug for Alzheimer's disease, is developing an electronic drug that uses vibroacoustic stimulation

On July 7, Remed disclosed clinical results showing that an electronic drug being developed by Remed was effective in patients with Alzheimer's disease. Remed is a Korean biotech company that has been identifying the potential of electronic drugs in various areas including depression, attention deficit hyperactivity